Literature DB >> 17889291

Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation.

Jordan E Scott1, Abdallah ElKhal, Eva-Jasmin Freyschmidt, Daniel H MacArthur, Douglas McDonald, Michael D Howell, Donald Y M Leung, Amale Laouar, N Manjunath, Teresa Bianchi, Marianne Boes, Hans C Oettgen, Raif S Geha.   

Abstract

BACKGROUND: Patients with atopic dermatitis (AD) exposed to the vaccinia virus (VV) smallpox vaccine have an increased risk of developing eczema vaccinatum.
OBJECTIVE: To investigate the effects of local allergic skin inflammation on vaccinia immunity.
METHODS: BALB/c mice were epicutaneously sensitized with ovalbumin (OVA) to induce allergic skin inflammation or with saline control, then inoculated with an attenuated VV strain by skin scarification or intraperitoneally. After 8 days, serum IgG anti-VV and cytokine secretion by splenocytes were measured.
RESULTS: Mice inoculated with VV at sites of epicutaneous sensitization with OVA, but not control mice inoculated at saline exposed sites, developed satellite pox lesions and had impaired secretion of T(H)1 cytokines in response to VV, decreased VV specific serum IgG(2a), increased VV specific serum IgG(1), and impaired upregulation of IFN-alpha, but not the cathelicidin-related antimicrobial peptide, at the infection site. The VV immune response of OVA-sensitized mice inoculated with VV at distant skin sites or intraperitoneally was normal.
CONCLUSION: Local immune dysregulation at sites of allergic skin inflammation underlies the impaired T(H)1 immune response to VV introduced at these sites and the increased susceptibility to develop satellite pox lesions, a characteristic of eczema vaccinatum in patients with AD. CLINICAL IMPLICATIONS: In a mouse model of AD, inoculation of VV at inflamed skin sites is associated with increased numbers of satellite pox lesions and an abnormal immune response to the virus. This may contribute to the susceptibility of patients with AD to virus dissemination after smallpox vaccination.

Entities:  

Mesh:

Year:  2007        PMID: 17889291     DOI: 10.1016/j.jaci.2007.08.004

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  15 in total

1.  Atopic conditions other than asthma and risk of the 2009 novel H1N1 infection in children: a case-control study.

Authors:  Carlos F Santillan Salas; Sonia Mehra; Maria R Pardo Crespo; Young J Juhn
Journal:  Allergy Asthma Proc       Date:  2013 Sep-Oct       Impact factor: 2.587

2.  Genome-wide analysis of polymorphisms associated with cytokine responses in smallpox vaccine recipients.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Iana H Haralambieva; Robert A Vierkant; Gregory A Poland
Journal:  Hum Genet       Date:  2012-05-19       Impact factor: 4.132

3.  Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis.

Authors:  U Darsow; M Sbornik; S Rombold; K Katzer; F von Sonnenburg; H Behrendt; J Ring
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-06-29       Impact factor: 6.166

4.  Interleukin-12 preserves the cutaneous physical and immunological barrier after radiation exposure.

Authors:  Scott A Gerber; Ryan J Cummings; Jennifer L Judge; Margaret L Barlow; Julee Nanduri; Doug E Milano Johnson; James Palis; Alice P Pentland; Edith M Lord; Julie L Ryan
Journal:  Radiat Res       Date:  2015-01-07       Impact factor: 2.841

Review 5.  Ionizing radiation: the good, the bad, and the ugly.

Authors:  Julie L Ryan
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

6.  IL-10 suppresses IL-17-mediated dermal inflammation and reduces the systemic burden of Vaccinia virus in a mouse model of eczema vaccinatum.

Authors:  Alanna R Darling; Eva-Jasmin Freyschmidt; Oliver T Burton; Kyle J Koleoglou; Michiko K Oyoshi; Hans C Oettgen
Journal:  Clin Immunol       Date:  2013-11-27       Impact factor: 3.969

7.  Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses.

Authors:  Eva-Jasmin Freyschmidt; Clinton B Mathias; Natalia Diaz; Daniel H MacArthur; Amale Laouar; Narasimhaswamy Manjunath; Matthias D Hofer; Marc-Andre Wurbel; James J Campbell; Talal A Chatila; Hans C Oettgen
Journal:  J Immunol       Date:  2010-06-14       Impact factor: 5.422

8.  Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.

Authors:  Kristina E Rehm; Rachel L Roper
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

9.  Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response.

Authors:  Michiko K Oyoshi; Abdallah Elkhal; Lalit Kumar; Jordan E Scott; Suresh Koduru; Rui He; Donald Y M Leung; Michael D Howell; Hans C Oettgen; George F Murphy; Raif S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

10.  Filaggrin deficiency promotes the dissemination of cutaneously inoculated vaccinia virus.

Authors:  Michiko K Oyoshi; Jacqueline Beaupré; Nicholas Venturelli; Christopher N Lewis; Yoichiro Iwakura; Raif S Geha
Journal:  J Allergy Clin Immunol       Date:  2015-01-30       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.